Loading...
MTAA
DIA
Market cap5.47bUSD
Apr 04, Last price  
93.26EUR
1D
1.66%
1Q
-6.16%
Jan 2017
65.80%
IPO
679.77%
Name

DiaSorin SpA

Chart & Performance

D1W1MN
P/E
31.22
P/S
4.35
EPS
2.99
Div Yield, %
1.23%
Shrs. gr., 5y
0.08%
Rev. gr., 5y
11.40%
Revenues
1.15b
-15.64%
147,336,000165,339,000179,756,000202,324,000244,612,000304,129,000404,547,000440,003,000433,763,000434,849,000443,770,000499,181,000569,312,000637,487,000669,197,000706,319,000881,305,0001,237,654,0001,361,138,0001,148,210,000
Net income
160m
-33.65%
3,623,0004,678,00022,294,00025,219,00037,459,00070,047,00090,418,00099,607,00087,396,00083,028,00084,074,000100,420,000112,383,000139,878,000158,128,000175,735,000247,871,000310,968,000240,907,000159,849,000
CFO
312m
-19.95%
24,460,00021,132,00033,976,00030,348,00047,779,00064,219,00095,791,000108,578,000110,582,000107,717,000119,847,000138,449,000165,597,000167,440,000209,879,000232,670,000304,562,000400,664,000389,341,000311,663,000
Dividend
May 20, 20241.15 EUR/sh
Earnings
May 08, 2025

Profile

DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIAISON XL, and LIAISON XL LAS; and molecular diagnostics platform comprising of LIAISON MDX for use in the amplification of nucleic acids to diagnose viral infections through the identification of virus in patient's biological sample. It has partnership agreements with QIAGEN for diagnostic solution for Latent Tuberculosis detection; TTP for the development of molecular Point-of-Care solution; and MeMed for the launch of a test differentiating between viral and bacterial infections. The company was founded in 1968 and is headquartered in Saluggia, Italy.
URL
https://www.diasorin.com/
IPO date
Jul 19, 2007
Employees
3,278
Domiciled in
IT
Incorporated in
IT

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,148,210
-15.64%
1,361,138
9.98%
Cost of revenue
911,145
964,166
Unusual Expense (Income)
NOPBT
237,065
396,972
NOPBT Margin
20.65%
29.16%
Operating Taxes
42,708
85,830
Tax Rate
18.02%
21.62%
NOPAT
194,357
311,142
Net income
159,849
-33.65%
240,907
-22.53%
Dividends
(58,967)
(57,052)
Dividend yield
1.13%
0.75%
Proceeds from repurchase of equity
(18,534)
116,142
BB yield
0.36%
-1.53%
Debt
Debt current
109,649
120,020
Long-term debt
1,154,005
1,301,467
Deferred revenue
Other long-term liabilities
70,752
80,041
Net debt
884,877
1,179,685
Cash flow
Cash from operating activities
311,663
389,341
CAPEX
(113,241)
(113,686)
Cash from investing activities
(29,102)
(231,952)
Cash from financing activities
(235,961)
(333,043)
FCF
237,640
242,352
Balance
Cash
378,751
413,218
Long term investments
26
(171,416)
Excess cash
321,366
173,745
Stockholders' equity
2,124,597
1,838,102
Invested Capital
2,480,008
2,764,245
ROIC
7.41%
11.85%
ROCE
7.90%
12.53%
EV
Common stock shares outstanding
55,746
58,050
Price
93.24
-28.50%
130.40
-22.13%
Market cap
5,197,751
-31.33%
7,569,704
-21.50%
EV
6,081,985
8,750,150
EBITDA
352,091
550,239
EV/EBITDA
17.27
15.90
Interest
34,966
Interest/NOPBT
8.81%